Restricted accessResearch articleFirst published online 2014-06
Bmi-1-shRNA Inhibits the Proliferation of Lung Adenocarcinoma Cells by Blocking the G1/S Phase Through Decreasing Cyclin D1 and Increasing p21/p27 Levels
B lymphoma Mo-MLV insertion region 1 (Bmi-1) is highly expressed in a variety of cancers and has been shown to regulate cell proliferation. The INK4a/ARF tumor suppressor gene locus is one of the major targets of Bmi-1. In the present study, we chose two lung adenocarcinoma cell lines, A549 cells (without INK4a locus) and SPC-A1 cells (with INK4a locus), to investigate if the small hairpin RNA-mediated knockdown of Bmi-1 could inhibit the proliferation of lung adenocarcinoma cells, and to delineate the possible mechanism underlying Bmi-1 modulation of cell proliferation. We also investigated the potential pathway underlying Bmi-1 regulation of lung adenocarcinoma cell proliferation in different genetic backgrounds. To this end, we used shRNA to knockdown Bmi-1 expression in lung adenocarcinoma cells, which led to inhibition of cell growth, colony formation in vitro, and tumorigenesis in vivo. In addition, phosphorylated Akt and cyclin D1 expression were downregulated, p21 and p27 levels were upregulated, and p16 expression remained unchanged in SPC-A1 cells. These data indicate that Bmi-1 might modulate the growth of lung adenocarcinoma cells in an INK4a-p16 independent pathway.
Get full access to this article
View all access options for this article.
References
1.
ABBAST., and DUTTAA. (2009). p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer., 9, 400–414.
2.
AGARWALM.L., AGARWALA., TAYLORW.R., CHERNOVAO., SHARMAY., and STARKG.R. (1998). A p53-dependent S-phase checkpoint helps to protect cells from DNA damage in response to starvation for pyrimidine nucleotides. Proc. Natl. Acad. Sci. U. S. A., 95, 14775–14780.
3.
BECKERM., KORNC., SIENERTHA.R., VOSWINCKELR., LUETKENHAUSK., CETECIF., and RAPPU.R. (2009). Polycomb group protein Bmi-1 is required for growth of RAF driven non-small-cell lung cancer. PLoS ONE, 4, e4230.
4.
BLANCOA.C., RENNERO., LEALJ.F., and CARNEROA. (2007). PTEN, more than the AKT pathway. Carcinogenesis, 28, 1379–1386.
5.
BREUERR.H., SNIJDERSP.J., SUTEDJAG.T., SEWALTR.G., and OTTEA.P. (2005). Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions. Lung Cancer, 48, 299–306.
6.
CUIH., MAJ., DINGJ., LIT., ALAMG., and DINGH.F. (2006). Bmi-1 regulates the differentiation and clonogenic self-renewal of I-type neuroblastoma cells in a concentration-dependent manner. J. Biol. Chem., 281, 34696–34704.
7.
DOUGLASD., HSUJ.H., HUNGL., COOPERA., ABDUEVAD., van DOORNINCKJ., PENGG., SHIMADAH., TRICHET.J., and LAWLORE.R. (2008). BMI-1 promotes Ewing sarcoma tumorigenicity independent of CDKN2A repression. Cancer Res., 68, 6507–6515.
8.
ENGELMANJ.A., LUOJ., and CANTLEYL.C. (2006). The evolution of phosphatidyliositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet., 7, 606–619.
9.
GLINSKYG.V., BEREZOVSKAO., and GLINSKIIA.B. (2005). Microarray analysis identifies a death from cancer signature predicting therapy failure in patients with multiple types of cancer. J. Clin. Invest., 115, 1503–1521.
10.
GUOW.J., ZENGM.S., YADAVA., SONGL.B., GUOB.H., BANDV., and DIMRIG.P. (2007). Mel-18 acts as a tumor suppressor by repressing Bmi-1 expression and downregulating Akt activity in breast cancer cells. Cancer Res., 67, 5083–5089.
11.
JACOBSJ.J., KIEBOOMK., MARINOS., DEPINHOR.A., and VAN LOHUIZENM. (1999). The oncogene and Polycomb group gene Bmi-1 regulates cell proliferation and senescence through the INK4a locus. Nature, 397, 164–168.
12.
KANGM.K., KIMR.H., KIMS.J., YIPF.K., SHINK.H., DIMRIG.P., CHRISTENSENR., HANT., and PARKN.H. (2006). Elevated Bmi-1 expression is associated with dysplastic cell transformation during oral carcinogenesis and is required for cancer cell replication and survival. Br. J.Cancer., 96, 126–133.
13.
KIMJ.H., YOONS.Y., KIMC.N., JOOJ.H., MOONS.K., CHOEI.S., CHOEY.K., and KIMJ.W. (2004). The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett., 203, 217–224.
14.
LESSARDJ.G. (2003). Bmi-1 determines the proliferative capacity of normal and leukemic stem cells. Nature, 423, 255–260.
15.
LIUS., DONTUG., MANTLEI.D., PATELS., and AHNN.S. (2006). Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res., 66, 6063–6071.
16.
MALUMBRESM., and BARBACIDM. (2009). Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer, 9, 153–156.
17.
MENGX.X., WANGY.F., ZHENGX.Y., LIUC.Q., SUB.L., NIEH.L., ZHAOB.X., ZHAOX.Y., and YANGH. (2012). shRNA-mediated knockdown of Bmi-1 inhibit lung adenocarcinoma cell migration and metastasis. Lung Cancer., 77, 24–30.
18.
OKAMOTOA., HUSSAINS.P., HAGIWARAK., SPILLAREE.A., RUSINM.R., DEMETRCKD.J., SERRANOM., HANNONG.J., SHISEKJM., and ZARIWALAM. (1995). Mutations in the P16INK4a/MTS1/ CDKN2, and P18 genes in primary and metastatic lung cancer. Cancer Res., 55, 1448–1451.
19.
POMERANTZJ., SCHREIBERA.N., LIEGEOISN.J., SILVERMANA., ALLANDL., CHINL., POTESJ., CHENK., ORLOWI., LEEH.W., et al. (1998). The INK4a tumor suppressor gene product p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell, 92, 713–723.
20.
SAWAM., YAMAMOTOK., YOKOZAWAT., KIYOIH., HISHIDAA., KAJIGUCHIT., SETOM., KOHNOA., KITAMURAK., ITOHY., et al. (2005). Bmi-1 is highly expressed in Mo-subtype acute myeloid leukemia. Int. J. Hematol., 82, 42–47.
21.
SONGL.B., LIJ., LIAOW.T., FENGY., and YUC.P. (2009). The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J. Clin. Invest., 119, 3626–3636.
22.
SONGL.B., ZENGM.S., LIAOW.T., ZHANGL., and MOH.Y. (2006). Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res., 66, 6225–6232.
23.
TASHIROE., TSUCHIYAA., and IMOTOM. (2007). Functions of cyclin D1 as an oncogene and regulation of Cyclin D1 expression. Cancer Sci., 98, 629–635.
24.
TOYOOKAS., TOKUMOM., SHIGEMATSUH., MATSUOK., and ASANOH. (2006). Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Res., 66, 1371–1375.
25.
VAN LOHUIZENM., VERBEEKS., SCHEIJENB., WIENTJENSE., and GULDENH. (1991). Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell, 65, 737–752.
26.
VIDALA., and KoffA. (2000). Cell-cyclin inhibitors: three families united by common cause. Gene, 247, 1–15.
27.
WUJ., HUD., YANGG., ZHOUJ., YANGC., GAOY., and ZHUZ. (2011). Down-regulation of Bmi-1 cooperates with Artemisinin on growth inhibition of nasopharyngeal carcinoma cells. J. Cell. Biochem., 112, 1938–1948.
28.
YUQ., SUB.L., LIUD.D., LIUB., and FANY. (2007). Antisense RNA-mediated suppression of Bmi-1 gene expression inhibits the proliferation of lung cancer cell line A549. Oligonucleotides, 17, 327–335.
